BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 04, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

MabThera rituximab regulatory update

CHMP issued a positive opinion to extend the indication of MabThera rituximab from Roche to include the treatment of follicular lymphoma in patients responding to induction therapy. CHMP is part of the European Medicines Agency (EMA)....

Read the full 160 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >